BR112023024034A2 - Polipeptídeos de sars-cov-2 - Google Patents

Polipeptídeos de sars-cov-2

Info

Publication number
BR112023024034A2
BR112023024034A2 BR112023024034A BR112023024034A BR112023024034A2 BR 112023024034 A2 BR112023024034 A2 BR 112023024034A2 BR 112023024034 A BR112023024034 A BR 112023024034A BR 112023024034 A BR112023024034 A BR 112023024034A BR 112023024034 A2 BR112023024034 A2 BR 112023024034A2
Authority
BR
Brazil
Prior art keywords
cov
sars
polypeptides
document provides
coronavirus
Prior art date
Application number
BR112023024034A
Other languages
English (en)
Inventor
A Poland Gregory
G Ovsyannikova Inna
B Kennedy Richard
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of BR112023024034A2 publication Critical patent/BR112023024034A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

polipeptídeos de sars-cov-2. este documento fornece métodos e materiais relacionados a polipeptídeos de coronavírus 2 (sars-cov-2) de desconforto respiratório agudo grave selecionados. por exemplo, este documento fornece composições de vacina que contêm um ou mais polipeptídeos de sars-cov-2 selecionados fornecidos neste documento e que têm a capacidade de induzir ou aumentar as respostas imunes contra coronavírus, como sars-cov-2, em um mamífero (por exemplo, um humano).
BR112023024034A 2021-05-20 2022-05-19 Polipeptídeos de sars-cov-2 BR112023024034A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163190964P 2021-05-20 2021-05-20
US202263341771P 2022-05-13 2022-05-13
PCT/US2022/030068 WO2022246084A1 (en) 2021-05-20 2022-05-19 Sars-cov-2 polypeptides

Publications (1)

Publication Number Publication Date
BR112023024034A2 true BR112023024034A2 (pt) 2024-02-06

Family

ID=82321637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024034A BR112023024034A2 (pt) 2021-05-20 2022-05-19 Polipeptídeos de sars-cov-2

Country Status (10)

Country Link
US (1) US20220370601A1 (pt)
EP (1) EP4294440A1 (pt)
JP (1) JP2024521098A (pt)
KR (1) KR20240012394A (pt)
AU (1) AU2022277697A1 (pt)
BR (1) BR112023024034A2 (pt)
CA (1) CA3212678A1 (pt)
IL (1) IL308465A (pt)
MX (1) MX2023013665A (pt)
WO (1) WO2022246084A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240042070A1 (en) * 2022-06-28 2024-02-08 Transcode Therapeutics, Inc. Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138876A1 (en) * 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
GB202011652D0 (en) * 2020-07-28 2020-09-09 Univ Oxford Innovation Ltd Polypeptide panels and uses thereof
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19

Also Published As

Publication number Publication date
AU2022277697A1 (en) 2024-01-04
US20220370601A1 (en) 2022-11-24
EP4294440A1 (en) 2023-12-27
CA3212678A1 (en) 2022-11-24
MX2023013665A (es) 2024-01-08
JP2024521098A (ja) 2024-05-28
WO2022246084A1 (en) 2022-11-24
IL308465A (en) 2024-01-01
KR20240012394A (ko) 2024-01-29

Similar Documents

Publication Publication Date Title
CL2019000268A1 (es) Composición de cannabis.
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
SV2018005778A (es) Derivados aromaticos de sulfonamida
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
ES2692773T3 (es) Tratamientos para la fibrosis
BR112015032341A2 (pt) conservação de composições para cuidados pessoais
BR112016025297A2 (pt) adenovírus que compreende uma porção de ligação a albumina
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
TR201908954T4 (tr) Akne tedavisi için bileşim.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
BR112016030983A8 (pt) composições para o tratamento de obesidade, prevenção de ganho de peso, promoção de perda de peso, promoção de emagrecimento, ou tratamento de ou prevenção do desenvolvimento de diabetes, kit, método para a preparação de tirfostina 9 e uso
BR112018067860A2 (pt) micróbios alimentados diretamente
CY1124010T1 (el) Μια φαρμακευτικη συνθεση για την παρεμποδιση της διατροφικης παχυσαρκιας
CL2020003010A1 (es) Moduladores de la expresión de apol1
BR112023024034A2 (pt) Polipeptídeos de sars-cov-2
AR113618A1 (es) Péptidos antimicrobianos y métodos para usarlos
BR112023026246A2 (pt) Modificação de pacotes mensageiros de planta
UY29417A1 (es) Agentes endoparasiticidas
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
BR112018069900A2 (pt) composição antimicrobiana, método de limpeza ou desinfecção de uma superfície e uso de um complexo fosfolipídico catiônico